xanthanine DPP-IV inhibitors (Boehringer Ingelheim)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug Namexanthanine DPP-IV inhibitors (Boehringer Ingelheim)
Drug Alias NameBI-14361BI-ABI-B
ClassificationSmall molecules
Mechanisms of ActionDipeptidyl peptidase IV inhibitors
TargetsDipeptidyl peptidase IV
Therapy Area/IndicationsSyndromeDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBoehringer Ingelheim International Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBoehringer Ingelheim International Gmbh
Active IndicationsN/A
Inactive IndicationsSyndromeDiabetes Mellitus, Type 2

Other Information

ATC CodeN/A
Related LinksN/A